Enveda, a biotechnology company leveraging artificial intelligence to accelerate drug discovery, has announced a $150 million Series D funding round, propelling the company to unicorn status with a valuation exceeding $1 billion. The funding will support the advancement of its AI-driven drug development platform and expand its pipeline of therapeutic candidates. In a significant milestone, Enveda has enrolled its first patient in a clinical trial for its lead program, marking a pivotal step from preclinical research to human testing. The trial is focused on a novel therapeutic approach targeting inflammatory and metabolic diseases, leveraging the company’s proprietary AI models trained on vast biological datasets. The company also announced the addition of Dr. Mikael Dolsten, former Chief Scientific Officer and President of Research and Development at Pfizer, to its Board of Directors. Dolsten brings decades of experience in drug development, clinical research, and biopharmaceutical innovation, offering strategic guidance as Enveda scales its operations and clinical pipeline. Enveda’s AI platform is designed to identify high-potential drug candidates by analyzing complex biological relationships and predicting therapeutic outcomes with greater speed and accuracy than traditional methods. The company’s approach integrates multi-omics data, real-world evidence, and machine learning to de-risk early-stage drug discovery. The Series D round was led by a consortium of institutional investors and strategic partners, underscoring growing confidence in AI-powered biotech and its potential to transform how medicines are discovered and developed. With the new capital, Enveda plans to expand its research teams, advance multiple programs into clinical development, and further refine its AI infrastructure. The company’s achievements—reaching unicorn status, initiating clinical trials, and securing top-tier board leadership—highlight its rapid progress in the competitive landscape of AI-driven pharmaceutical innovation.